A recent study in hepatocellular carcinoma (HCC) identified a five-gene natural killer cell-related signature (NKRLSig), which included CHP1, and demonstrated that patients in the low-risk group exhibited improved responses to immunotherapy [65]. The gene discussed is CHP1; the disease is hepatocellular carcinoma.